VicOryx
Solid Cancers
Phase 1/2Active
Key Facts
About Oryx Translational Medicine
Oryx Translational Medicine is a private, Munich-based biotech company founded in 2018 with a distinctive 'academic-to-pharma' bridge model. It specializes in advancing early-stage academic oncology discoveries, particularly in RNA/gene therapy, vaccines, and viral technology, through to clinical proof-of-concept. The company has a lean operational structure, leveraging in-house expertise and outsourced execution to build a capital-efficient pipeline, with three programs that have already demonstrated safety and early efficacy signals in clinical trials. Its strategy is to de-risk innovative therapies for subsequent partnership with larger pharmaceutical companies.
View full company profileTherapeutic Areas
Other Solid Cancers Drugs
| Drug | Company | Phase |
|---|---|---|
| TROCEPT-01 (ATTR-01) | Accession Therapeutics | Phase 1 |
| Two GATE™ (Undisclosed Targets) | Revitope Oncology | Preclinical |
| MicOryx | Oryx Translational Medicine | Phase 1/2 |
| Undisclosed TCR Program(s) | Captain T Cell | Pre-clinical |